ADWIA Pharmaceuticals

What ADWIA Pharmaceuticals does

ADWIA Pharmaceuticals is an Egyptian privately-held generic pharmaceutical manufacturer founded in 1984 and headquartered in New Cairo. The company operates two parallel divisions — Human Health and Animal Health — and runs an EDA-licensed manufacturing facility in 10th of Ramadan City that produces roughly 50+ branded generic molecules spanning anti-infectives, cardiology, orthopedics, gastroenterology, urology, men's health, CNS, anti-asthmatics, and veterinary products (antibiotics, anthelmintics, anti-inflammatories, vitamins, and electrolytes).

The company operates a traditional pharmaceutical manufacturing model under a multi-layered compliance regime that includes GMP, GLP, GSP, EDA, WHO, ISO 9001, ISO 14001, ISO 45001, and ISO 50001 certifications, with a Pharmaceutical Quality System (PQS) aligned to Quality Risk Management. Distribution is handled through domestic Egyptian wholesale and pharmacy networks plus regional distribution partnerships covering GCC countries (Saudi Arabia, UAE, Kuwait, Bahrain, Oman, Qatar), CIS regions, and African nations.

ADWIA is led by founder-Chairman and CEO Dr. Mohamed Khattab alongside a functional director team spanning commercial, medical/pharmacovigilance, finance, HR, supply chain, compliance, technical operations, and strategic planning/business development. The company is founder/management-owned with no disclosed institutional investors, no funding rounds, and no M&A activity on record. Recent commercial activity includes the 2025 launch of Voxazoldin (linezolid), the Annual Meeting 2025 commercial kickoff, and 2024 recognition by the Egyptian Drug Authority for contributions to pharmaceutical exports.

Name

ADWIA Pharmaceuticals

Legal name

ADWIA Pharmaceuticals

Website

https://adwia.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ADWIA Pharmaceuticals is an Egyptian privately-held generic drug manufacturer founded in 1984, producing 50+ branded generics across human and animal health for the domestic Egyptian market and export distribution in GCC, CIS, and African countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Generic pharmaceuticals
• Human health medications
• Animal health products
• Pharmaceutical manufacturing
• Therapeutic formulations

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: ADWIA generates revenue through manufacturing and selling generic pharmaceutical medications for human and animal health. The company produces drugs across multiple therapeutic categories including cardiovascular, orthopedic, urology, gastroenterology, anti-infectives, CNS, and veterinary medications.
2. Export/Distribution: Revenue from export of pharmaceutical products to international markets including GCC countries, CIS regions, and African nations through distribution partnerships.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

ADWIA Pharmaceuticals manufactures and markets a diversified portfolio of generic pharmaceutical products for human health (anti-infectives, cardiovascular, orthopedic, urology, men's health, gastroenterology, CNS, anti-asthmatic, antifungal, cough/cold, and analgesic medications) and animal health (antibiotics, anthelmintics, anti-inflammatories, vitamins, minerals, electrolytes, sedatives, analgesics, anesthesia). Production occurs at an EDA-licensed facility in 10th of Ramadan City under WHO, GMP, GLP, GSP, EDA, and ISO quality standards, with products distributed domestically in Egypt and exported to GCC, CIS, and African markets.

Product overview

ADWIA Pharmaceuticals is an Egyptian pharmaceutical company established in 1984 specializing in manufacturing high-quality generic medications for both human and animal health. The company operates through two main divisions: Human Health Division and Animal Health Division. Human health products span therapeutic categories including anti-infective (Wincef, Voxazoldin, Sulcefozone, Mirage IV, Adwifloxacen), orthopedic/musculoskeletal (Vegapantin, Osteonate, Anticox II, Adwitine, Adwimove, Adwiflam), gastroenterology (Block alpha, Gesomezol, Trustnal, Spasmofree, Danset), urology (Uripan, Prostride, Incont), men's health (Erec, Predapox), cardiometabolic (Right-Ace, Randil, Myogrel, Ezastatin, Crestatin, Adwivalsar, Adwistadine), CNS/psychiatric (Adwiprazole, Leptrogine, Mantine, SESERINE), anti-asthmatic (Statukast), cough and cold (Antiflu), non-narcotic analgesics (AMADOL), and antifungal (Itranox). Animal health products include antibiotics, anthelmintics, anti-inflammatories, vitamins, minerals, electrolytes, and sedatives for veterinary applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Health Division Diversified portfolio of generic pharmaceutical products for human health spanning anti-infective, orthopedic, gastroenterology, urology, men's health, antifungal, gynecology, oral hygiene, anti-asthmatic, cardiometabolic, non-narcotic analgesics, cough and cold, and CNS therapeutic categories, supplied to healthcare providers, hospitals, and pharmacies.
• Animal Health Division Veterinary pharmaceutical products including antibiotics, anthelmintics, anti-inflammatories, vitamins, minerals, electrolytes, sedatives, analgesics, and anesthesia products for livestock and animals, supplied to veterinarians and animal health professionals.
• Wincef Vial 1gm Antibiotic injection containing cefepime for treatment of respiratory tract infections, urinary tract infections, skin infections, intra-abdominal infections, gynecological infections, bacterial meningitis, and neutropenic patients with fever.
• Voxazoldin Antibiotic containing linezolid 600mg film-coated tablet for treatment of community-acquired pneumonia, nosocomial pneumonia, and complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria.
• Sulcefozone 500mg Injectable antibiotic combining sulbactam sodium and cefoperazone for treatment of respiratory tract infections, urinary tract infections, peritonitis, septicemia, meningitis, skin infections, and bone and joint infections.
• Mirage IV Intravenous antibiotic containing meropenem for treatment of severe pneumonia, complicated urinary tract infections, intra-abdominal infections, skin infections, meningitis, and management of neutropenic patients.
• Adwifloxacen 400mg Film-coated tablet containing moxifloxacin 400mg for treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, complicated skin infections, and pelvic inflammatory disease.
• Vegapantin Film-coated tablet containing gabapentin 600mg for management of postherpetic neuralgia and as adjunctive therapy for partial seizures in patients over 12 years.
• Osteonate 70mg Tablet containing alendronate sodium for treatment of postmenopausal osteoporosis, reducing risk of vertebral and hip fractures.
• Anticox II Meloxicam-based product line (capsules 7.5mg, tablets 15mg, suppositories, and injection) for symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
• Adwitine Duloxetine 30mg, 60mg Delayed-release capsules containing duloxetine for treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.
• Adwiflam Diclofenac potassium product line in multiple forms (suppositories 12.5/25/75mg, sachets 50mg, extended-release capsules 50mg) for relief of pain and inflammation in arthritic conditions, musculoskeletal disorders, and post-operative pain.
• Block alpha 0.4 MR Capsules Modified-release capsules containing tamsulosin HCl 0.4mg for treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
• Gesomezol Capsules containing esomeprazole 40mg for treatment of erosive reflux esophagitis, GORD, H. pylori eradication, NSAID-induced ulcers, and Zollinger-Ellison syndrome.
• Trustnal Subs Nitazoxanide tablets 500mg and oral suspension 100mg/5ml for treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
• Spasmofree Tiemonium methyl sulfate product line (tablets 50mg, syrup, and injection 5mg/2ml) for symptomatic treatment of functional GI disorders, biliary tract conditions, gynecological manifestations, and urinary tract spasms.
• Danset Ampoules Ampoules containing ondansetron 4mg/2ml or 8mg/4ml for management of nausea and vomiting induced by chemotherapy, radiotherapy, and post-operative nausea and vomiting.
• Uripan Oxybutynin hydrochloride product line (syrup 5mg/5ml and extended-release tablets 10mg) for treatment of urinary incontinence, urgency, and frequency in unstable or overactive bladder conditions.
• Prostride Capsules Hard gelatin capsules containing finasteride 5mg for treatment and control of benign prostatic hyperplasia (BPH) to improve urinary flow and reduce need for surgery.
• Incont Tablets Long-acting tablets containing tolterodine tartrate 4mg for symptomatic treatment of urge incontinence and increased urinary frequency in overactive bladder syndrome.
• Erec 100mg Film-coated tablets containing sildenafil citrate 140.48mg (equivalent to 100mg sildenafil) for treatment of erectile dysfunction in adult men.
• Predapox Film-coated tablets containing dapoxetine hydrochloride 30mg for treatment of premature ejaculation in adult men aged 18 to 64 years.
• Statukast Montelukast sodium product line (film-coated tablets 10mg and chewable tablets 4mg) for prophylaxis and chronic treatment of asthma and prevention of exercise-induced bronchoconstriction, including pediatric indications.
• Right-Ace Ramipril product line (5mg, 10mg tablets and fixed-dose combination with hydrochlorothiazide 25mg) for treatment of essential hypertension, cardiovascular prevention, renal disease, symptomatic heart failure, and secondary prevention after acute myocardial infarction.
• Randil 10mg & 20mg Tablets Scored tablets containing nicorandil 10mg or 20mg for symptomatic treatment of stable angina pectoris in patients inadequately controlled on first-line antianginal therapies.
• Myogrel Clopidogrel-based product line (film-coated tablets 75mg/300mg and fixed-dose combination with ASA 75mg) for secondary prevention of atherothrombotic events, acute coronary syndrome, and prevention in atrial fibrillation.
• Ezastatin Fixed-dose combination tablets containing ezetimibe 10mg and atorvastatin for treatment of primary hypercholesterolaemia and homozygous familial hypercholesterolaemia.
• Crestatin Film-coated tablets containing rosuvastatin calcium 5.197mg (equivalent to 5mg rosuvastatin) for treatment of hypercholesterolaemia and prevention of cardiovascular events.
• Adwivalsar Valsartan product line (film-coated tablets 160mg and fixed-dose combination with hydrochlorothiazide 12.5mg/25mg) for treatment of essential hypertension, post-myocardial infarction, and symptomatic heart failure.
• Adwistadine Scored film-coated tablets containing ivabradine 5mg or 7.5mg for treatment of coronary artery disease, symptomatic chronic stable angina pectoris, and chronic heart failure.
• AMADOL Hard gelatin capsules containing tramadol hydrochloride 50mg for treatment and prevention of moderate to severe pain.
• Adwiprazole Tablets containing aripiprazole 10mg or 30mg for treatment of schizophrenia in adults and adolescents 15 years and older, and treatment of moderate to severe manic episodes in Bipolar I Disorder.
• Leptrogine 200mg & 25mg Tablets and chewable tablets containing lamotrigine 200mg for epilepsy treatment (adjunctive or monotherapy for partial seizures, generalized seizures, Lennox-Gastaut syndrome) and bipolar disorder.
• SESERINE 50mg Tablets Tablets containing sertraline hydrochloride equivalent to 50mg sertraline for treatment of major depressive episodes, panic disorder, OCD, social anxiety disorder, and PTSD.
• Mantine 10mg Tablets containing memantine hydrochloride 10mg (equivalent to 8.31mg memantine) for treatment of patients with moderate to severe Alzheimer's disease.
• Itranox Capsules Hard gelatin capsules containing itraconazole for treatment of vulvovaginal candidiasis, oral candidiasis, dermatophytoses, pityriasis versicolor, onychomycosis, cryptococcosis, aspergillosis, and histoplasmosis.
• Antiflu Hard Gelatin Capsules Capsules containing ibuprofen 200mg, pseudoephedrine hydrochloride 60mg, chlorpheniramine maleate 3mg, and caffeine 25mg for temporary relief of common cold symptoms.
• Vetragin 50 Injectable veterinary solution for analgesic and antipyretic applications in animals.
• Adwimove Topical Gel Topical gel containing salicylic acid and mucopolysaccharides polysulphoric acid ester for symptomatic relief of muscular pain, stiffness, sprains, strains, and rheumatic conditions.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• EIPICO (Egyptian International Pharmaceutical Industries Company): Largest Egyptian generic pharmaceutical manufacturer with a comparable diversified human-health generics portfolio and export presence; the most direct local competitor to ADWIA across therapeutic categories.
• Eva Pharma: Egyptian pharmaceutical manufacturer producing generic medications across multiple therapeutic areas with strong domestic share and growing export footprint in MENA/Africa, directly comparable to ADWIA's business model.
• Pharco Pharmaceuticals: One of Egypt's largest generic pharma producers with broad therapeutic coverage and significant export activity, making it a close comparable in scale, therapeutic breadth, and regional reach.

Broad incumbents

• Hikma Pharmaceuticals: Jordan-headquartered multinational with a large MENA-focused generic pharmaceuticals business and injectable manufacturing; a broader incumbent competing with ADWIA across overlapping export markets and product categories.
• Cipla: Indian global generic pharmaceutical manufacturer with major presence in Africa and emerging markets; competes with ADWIA in anti-infectives, respiratory, and cardiometabolic categories across African export markets.
• Aurobindo Pharma: Large Indian generic manufacturer with extensive emerging-market export operations including Africa; a comparable scale competitor in finished generic formulations across similar therapeutic categories.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer serving the GCC market with a similar broad generics portfolio; comparable in scale and product mix to ADWIA but primarily operating across GCC rather than Africa/CIS.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi Arabian generic and OTC pharmaceutical manufacturer with similar diversified portfolio across therapeutic categories; a regional peer competing for MENA share and government tenders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ADWIA.Pharmaceuticals

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADWIA Pharmaceuticals